At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed, completely resected stage IA (pT1, N0) or IB (pT2, N0) non-small cell lung cancer (except carcinoid)
- ✓Completion of treatment within past 6 to 36 months and currently disease-free
- ✓At least one mediastinal lymph node sampled at resection
- ✓Age 18 years and over
- ✕Evidence of new or recurrent lung cancer on chest x-ray within past 8 weeks
- ✕Synchronous lung or non-lung lesions or metastasis, even if resectable
- ✕History of more than one primary lung cancer at any time
- ✕Concurrent or other prior cancer within past 5 years except localized non-melanoma skin cancer
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III Chemoprevention Trial Of Selenium Supplementation In Persons With Resected Stage I Non-Small Cell Lung Cancer
In Brief
A Phase 3 clinical trial evaluating placebo and selenium for Lung Cancer. Completed, enrolled 1,772 participants across 532 sites in 2 countries.
Detailed Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. It is not yet known if selenium is effective in preventing the growth of new tumors in patients with previously resected non-small cell lung cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared to a placebo in preventing the development of second primary lung tumors in patients who have undergone surgery to remove stage I non-small cell lung cancer.
Study Details
Timeline
Interventions
Given orally
Given orally